Stop staring at a 6.50-8$ stock everyday making up stuff-
their is huge put volume= they sold 600 after release yesterday to cover their hedge-
Nothing has changed and in fact the news has gotten dramatically better. Their is massive uncertainty obvious with whats going on with the government- when that happens everybody buys liquidity and stays away from riskier assets. Their is no volume in the stock to justify my position. The simple fact Affy has hit all its milestones and when everything calms down the market will give it a real value.
This whole country micromanages everything or stares at stocks minute to minute- who cares if affy is 6.70or 8$ like it was last week- if your a speculator and lost money because their wasnt a pump thats your problem so stop crying. If you believe the drug will get approved everything just moved forward and looks great. Go enjoy you kids and the sun and let it play out.
well said. We should discuss the merits of the product, commercial opportunity, regulatory risk etc. Instead idiots result to name calling and worry about the recent cash raise and the former CEO. Money will be made by those who understand how to make real money by assigning probablities of success and not pennies on day trading.
Today their is never a stronger time for why Takeda will not takeout affy- They already invested ard 300 million and have to pay them another 95million when the drug is approved- Takeda has and is looking for takeovers-thats a fact-google it. This has to be the number 1 takeover potential for biotechs in the space= just common sense.
With all this cash, the obvious question is why doesn’t Takeda take advantage of the current situation and offer a buyout at a substantial premium to its current price? It would be very cost effective: Takeda would recapture much of the $250 million it has paid out to AFFY, avoid paying the additional $125 million in milestones upon FDA approval, and receive 100% of future Hematide revenues instead of 50%. What would that be worth? A quick guess would be at least $400 million, or $16 per share, a great deal for Takeda and current AFFY shareholders. At this point, I suspect AFFY shareholders who own AFFY in the $20 range would take the deal as well. I am not a big fan of buyout speculation, but AFFY lacks a “poison pill” for a takeover, and in this case this scenario seems too tempting for Takeda. Buying down here in the $5-$6 range seems like a low risk investment, with lots of upside due to a potential buyout or the more likely FDA approval of Hematide.
Amen, 95% of the posts on this board are from children, or dopes. I bought back 50 puts myself yesterday and was surprised anyone would pay what they paid, but I will take it. No need for $6 puts now.